The Group obtains approval of the CetilarĀ®Ā patent in the USA and new prospects unfold for SiderALĀ® in India thanks to […]
The new patent, valid until 2037, opens PharmaNutra up to the possibility of developing specific products for the cardiovascular field, […]
After Europe, the intellectual property rights of the patent expiring in 2033 are now acknowledged in the United States. A […]